Back
CYP2D6HGNC PubMed

A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 Allelic Percentage Activity from the International CEPAM Database

Klima F, Helland T, Michelet R, et al. — Clin Pharmacol Ther 2026 · November 2026
Relevance score
7/10
Disease / domain
Variability in exposure to CYP2D6-metabolised drugs (model: tamoxifen)
Source
PubMed
PMID 43015984

Gene–drug pair / mechanism

CYP2D6

Mixed-effects modelling of the CEPAM database to estimate the percentage activity of each CYP2D6 allele, using Z-endoxifen under tamoxifen

Summary

Current dosing recommendations rely on drug-agnostic categorical activity values for CYP2D6 star alleles. The authors estimated allelic percentage activity (0% to 100%, reference CYP2D6*1) by nonlinear mixed-effects modelling of the international CEPAM database (more than 7,000 patients, 31 studies), using tamoxifen and Z-endoxifen as the model substrate. Several estimated activities deviate markedly from the categorical values: 64-68% for CYP2D6*2 and CYP2D6*35 (value 1), 29% for CYP2D6*17 and CYP2D6*29 (value 0.5), and 52% for CYP2D6*9 (value 0.25). Each additional allele copy carries 68% of the activity of the first, less than the doubling assumed by categorical values. Using percentages instead of categorical values changes predicted individual Z-endoxifen concentrations by -22.3% to +40.0%.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

The value lies in the principle: moving from an activity class to a percentage shifts predicted concentrations by up to 40%, which challenges the current genotype-to-phenotype translation. But the demonstration rests on a single substrate, tamoxifen, and the authors state that the substrate specificity of these values remains to be evaluated. One to follow as a possible revision of the activity system, with no change in practice before prospective validation.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 2/3Novelty 1/2Sample 1/1Publication 1/1

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10

Keywords

CYP2D6tamoxifenstar allelesactivity scorepharmacogenetics

More articles on CYP2D6

Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime